en · de · es · fr · pt
field-notes.peptides3081.com › Topic › Tb-500 Identity And Molecular Background — Practical Notes

Tb-500 Identity And Molecular Background — Practical Notes

By Editorial Desk · published 2025-10-11 · last reviewed 2025-11-29 · Topic

TB-500 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2025-11-29 and is reviewed periodically as new material appears.

TB-500 Identity and Molecular Background

Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.

Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.

TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.

Thymosin Beta-4 Fragment Background

Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.

TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.

Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.

Tb-500 at a glance

PropertyValueNotes
Molecular formulaC38H68N10O14Calculated for the acetylated heptapeptide
Molecular weight~889 DaMonoisotopic mass approximately 889.0 Da
Amino acid sequenceAc-LKKTETQN-terminal acetylated seven-residue peptide
AppearanceWhite to off-white powderTypically supplied as a lyophilized solid
Solubility classWater-solublePeptides of this size generally dissolve in aqueous media

Identity and Reported Background

Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.

TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.

Related pages on this site

Handling, Storage, and Quality Control

Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.

Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.

Handling, Storage, and Analytical Verification

Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.

Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.

The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.

Reference notes

The procedure worked and the body showed no signs of decomposition when Eva was interred at her final resting place many years after the initial procedure. Kemal Atatürk was embalmed. His remains were originally laid to rest in the Ethnography Museum of Ankara from 10 November 1938 to 10 November 1953. He was subsequently moved to Anıtkabir in Ankara, Turkey, buried in a 42-ton sarcophagus. Chiang Kai-shek and Chiang Ching-kuo were embalmed and rest at Cihu Mausoleum and Touliao Mausoleum in Daxi District, Taoyuan City, Taiwan. Francisco Franco was embalmed. His remains were originally laid to rest in the Valley of the Fallen from 1975 to 2019. He was subsequently moved to Mingorrubio Cemetery, El Pardo, Madrid, Spain. Ferdinand Marcos was embalmed in Hawaii upon his death. His body was flown home and was on display at the Marcos Museum and Mausoleum in Batac, Ilocos Norte, Philippines from 1993 to 18 November 2016. Diana, Princess of Wales was embalmed shortly after her death in France in August 1997. The decision to embalm her provoked conspiracy theories that she was pregnant; conspiracists claimed, incorrectly, that the embalming fluid would have destroyed any evidence of fetal presence in her womb. The official explanation for the embalming was that the warm conditions in the chapel of rest where her body was laid out would have sped up the decomposition of the remains.

== External links == IGF-1+Receptor at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Overview of all the structural information available in the PDB for UniProt: P08069 (Insulin-like growth factor 1 receptor) at the PDBe-KB.

== Characterization == Several qualitative tests are used to detect the presence of reducing sugars. Two of them use solutions of copper(II) ions: Benedict's reagent (Cu2+ in aqueous sodium citrate) and Fehling's solution (Cu2+ in aqueous sodium tartrate). The reducing sugar reduces the copper(II) ions in these test solutions to copper(I), which then forms a brick red copper(I) oxide precipitate. Reducing sugars can also be detected with the addition of Tollens' reagent, which consist of silver ions (Ag+) in aqueous ammonia. When Tollens' reagent is added to an aldehyde, it precipitates silver metal, often forming a silver mirror on clean glassware. 3,5-dinitrosalicylic acid is another test reagent, one that allows quantitative detection. It reacts with a reducing sugar to form 3-amino-5-nitrosalicylic acid, which can be measured by spectrophotometry to determine the amount of reducing sugar that was present. Some sugars, such as sucrose, do not react with any of the reducing-sugar test solutions. However, a non-reducing sugar can be hydrolyzed using dilute hydrochloric acid. After hydrolysis and neutralization of the acid, the product may be a reducing sugar that gives normal reactions with the test solutions. All carbohydrates are converted to aldehydes and respond positively in Molisch's test. But the test has a faster rate when it comes to monosaccharides.

=== Cardiogenesis === Development of heart is involved in several rounds of EMT and MET. While development splanchnopleure undergo EMT and produce endothelial progenitors, these then form the endocardium through MET. Pericardium is formed by sinus venosus mesenchymal cells that undergo MET. Quite similar processes occur also while regeneration in the injured heart. Injured pericardium undergoes EMT and is transformed into adipocytes or myofibroblasts which induce arrhythmia and scars. MET than leads to the formation of vascular and epithelial progenitors that can differentiate into vasculogenic cells which lead to regeneration of heart injury.

The Racial Discrimination Act 1975 created the first general right against race discrimination. However, in 2019 the median adjusted weekly household income for Indigenous Australians over 15 was just $623 compared to $935 for non-Indigenous residents, a 33.3% race pay gap. In 2016, the census showed a gap of 72% employment for non-Indigenous Australians to just 47% employment rate for Indigenous Australians. There have not yet been institutions to set aside a portion of the funds from Australia's natural resources for Indigenous Australian well-being, nor are there yet clear principles established to ensure that historic disadvantage is undone, as in South Africa, India, or Europe, through positive action.

Sources: en.wikipedia.org

Notes from published material

The three substrates of this enzyme are hydroxy-1,4-benzoquinone, reduced nicotinamide adenine dinucleotide (NADH), and a proton. Its products are hydroxyquinol and oxidised NAD+. This enzyme participates in the metabolism of 2,4,5-trichlorophenoxyacetic acid in the bacteria Burkholderia cepacia.

The same equations can be applied to the dual of current in an inductor. Furthermore, the particular case of a capacitor or inductor changing through several parallel resistors makes an interesting example of multiple decay processes, with each resistor representing a separate process. In fact, the expression for the equivalent resistance of two resistors in parallel mirrors the equation for the half-life with two decay processes. Geophysics: Atmospheric pressure decreases approximately exponentially with increasing height above sea level, at a rate of about 12% per 1000m. Heat transfer: If an object at one temperature is exposed to a medium of another temperature, the temperature difference between the object and the medium follows exponential decay (in the limit of slow processes; equivalent to "good" heat conduction inside the object, so that its temperature remains relatively uniform through its volume). See also Newton's law of cooling. Luminescence: After excitation, the emission intensity – which is proportional to the number of excited atoms or molecules – of a luminescent material decays exponentially. Depending on the number of mechanisms involved, the decay can be mono- or multi-exponential. Pharmacology and toxicology: It is found that many administered substances are distributed and metabolized (see clearance) according to exponential decay patterns. The biological half-lives "alpha half-life" and "beta half-life" of a substance measure how quickly a substance is distributed and eliminated.

Recent advances in analytical chemistry have enabled high-precision measurements of multiply substituted (or 'clumped') isotopologues like 13CH32H. This is a novel tool for studying methane formation. This proxy is based on the abundance of clumped isotopologues of methane, which should be enriched compared to the stochastic distribution at thermodynamic equilibrium because the reduced zero-point energy for heavy-heavy isotope bonding is more than twice the reduced zero-point energy of heavy-light isotope bonding. The extent of enrichment decreases with increasing temperature, as higher entropy tends to randomize isotope distribution. Stolper et al. established this temperature calibration using laboratory equilibrated methane and field methane from known formation temperature, and applied this to several gas reservoirs to study natural gas formation and mixing. Wang et al. also reported strong non-equilibrium isotope effect in methane clumped isotopes from lab-cultured methanogens and field samples. These methane samples have relatively low abundance of clumped isotopologues, sometimes even lower than the stochastic distribution. This indicates that there are irreversible steps in enzymatic reactions during methanogenesis that fractionation against clumped isotopologues to create the depleted signal. Isotope clumping in methane has proven a robust proxy, and scientists are now moving towards higher-order alkane molecules like ethane for further work.

=== Change in anti-terrorist policy and "peripheral" nationalisms === The PP government developed an anti-terrorist policy based on an idea that no democratic government had defended until then: that only police measures could put an end to ETA. Thus, the only possible "dialogue" with ETA was the handing over of weapons. The government reaped a resounding first success with the release in early July 1997 of José Ortega Lara, a prison officer and PP militant who had been held hostage by ETA for 532 days. But a few days later, on July 10, an event took place that would open a new stage in the history of the "Basque conflict". That day ETA kidnapped Miguel Ángel Blanco, a young PP councilman from the Biscayan town of Ermua, which provoked the largest social mobilization against terrorism in living memory. But after the deadline given for the prisoners of the organization to be transferred to prisons in the Basque Country, ETA assassinated Miguel Ángel Blanco, which increased even more the rejection of ETA and its "political arm", Herri Batasuna. The press began to use the term "spirit of Ermua" to explain that immense anti-terrorist social mobilization. In March 1998, the lehendakari José Antonio Ardanza announced a "Pacification Plan" in which, based on the Ajuria Enea Pact of 1988, he proposed that after achieving the cessation of ETA's violence, a dialogue should be opened between all the Basque political forces, the result of which should be accepted by the central government and the rest of the institutions of the State.

Sources: en.wikipedia.org

Frequently asked questions

What is TB-500?

TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.

Is TB-500 identical to thymosin beta-4?

No. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only a short N-terminal segment. The two should not be treated as interchangeable in experimental design.

How does TB-500 appear in the literature?

It is often called a thymosin beta-4 fragment, Tβ4 fragment, or Ac-LKKTETQ. The name TB-500 is mainly a commercial or catalog label rather than a formal chemical name.

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.

Network